Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro

Nathwani,Seema-Maria; Hughes,Linda; Greene,Lisa  M.; Carr,Miriam; O'Boyle,Niamh  M.; McDonnell,Susan; Meegan,Mary  J.; Zisterer,Daniela  M.

doi:10.3892/or.2012.2181

Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro

Authors:
- Seema-Maria Nathwani
- Linda Hughes
- Lisa M. Greene
- Miriam Carr
- Niamh M. O'Boyle
- Susan McDonnell
- Mary J. Meegan
- Daniela M. Zisterer
View Affiliations

Affiliations: School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland, UCD School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, Ireland, School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland
Published online on: December 10, 2012 https://doi.org/10.3892/or.2012.2181
Pages: 585-594

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Combretastatin A-4 (CA-4) is a naturally occurring microtubular-destabilising agent that possesses potent anti-tumour and anti-vascular properties both in vitro and in vivo. Clinical trials to date indicate that its water-soluble prodrug, combretastatin A-4 phosphate (CA-4P), is well tolerated at therapeutically useful doses. However, the stilbenoid structure of CA-4, consisting of two phenyl rings linked by an ethylene bridge, renders the compound readily susceptible to isomerisation from its biologically active cis-conformation to its more thermodynamically stable but inactive trans-isomer. To circumvent this problem, we synthesised a series of cis-restricted CA-4 analogues. Replacement of the ethylene bridge with a 1,4-diaryl-2-azetidinone (β-lactam) ring provided a rigid scaffold thus preventing cis-trans isomerisation. We previously documented that these tubulin-depolymerising β-lactam compounds potently induced cell cycle arrest and apoptosis in a variety of cancerous cell lines (including those displaying multidrug resistance) and ex vivo patient samples, whilst exerting only minimal toxicity to normal cells. The purpose of this study was to elucidate the effect of the β-lactam compounds on both tumour vascularisation and tumour cell migration, two critical elements that occur during the growth and metastatic progression of tumours. We established that two representative β-lactam compounds, CA-104 and CA-432, exerted both anti-endothelial effects [G2/M arrest and apoptosis of primary human umbilical vein endothelial cells (HUVECs)] and anti-angiogenic effects [inhibition of HUVEC migration and differentiation and reduced vascular endothelial growth factor (VEGF) release from MDA-MB-231 breast adenocarcinoma cells]. In addition, we established that lead analogue, CA-432, abrogated the migration of MDA-MB-231 cells indicating an anti-metastatic function for these compounds. In summary, our results to date collectively indicate that these cis-restricted β-lactam CA-4 analogues may prove to be useful alternatives to CA-4 in the treatment of cancer but with the added advantage of improved stability of the cis-isomer.

View Figures

View References

1	Pettit GR, Singh SB, Niven ML, Hamel E and Schmidt JM: Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod. 50:119–131. 1987. View Article : Google Scholar : PubMed/NCBI
2	Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR and Hamel E: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol. 34:200–208. 1988.PubMed/NCBI
3	Mollinedo F and Gajate C: Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 8:413–450. 2003. View Article : Google Scholar : PubMed/NCBI
4	Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45:209–211. 1989. View Article : Google Scholar : PubMed/NCBI
5	Nabha SM, Wall NR, Mohammad RM, Pettit GR and Al-Katib AM: Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs. 11:385–392. 2000. View Article : Google Scholar : PubMed/NCBI
6	Pettit GR, Temple C Jr, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA and Bansal N: Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 10:299–309. 1995.PubMed/NCBI
7	Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1829–1834. 1997.PubMed/NCBI
8	Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 81:1318–1327. 1999. View Article : Google Scholar : PubMed/NCBI
9	Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L and Price PM: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 21:2815–2822. 2003. View Article : Google Scholar : PubMed/NCBI
10	Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, Taylor NJ, Stirling JJ, Lu SP, Leach MO, Rustin GJ and Judson I: Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 18:3428–3439. 2012. View Article : Google Scholar : PubMed/NCBI
11	Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN and Remick SC: A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 19:233–240. 2009. View Article : Google Scholar
12	A service of the U.S. National Institutes of Health. www.clinicaltrials.govurisimplewww.clinicaltrials.gov. Accessed September 14, 2012
13	Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B and Tozer GM: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21:93–102. 2001.PubMed/NCBI
14	Kanthou C and Tozer GM: The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood. 99:2060–2069. 2002. View Article : Google Scholar
15	Pettit GR, Rhodes MR, Herald DL, Hamel E, Schmidt JM and Pettit RK: Antineoplastic agents. 445 Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41. J Med Chem. 48:4087–4099. 2005. View Article : Google Scholar : PubMed/NCBI
16	Woods JA, Hadfield JA, Pettit GR, Fox BW and McGown AT: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer. 71:705–711. 1995. View Article : Google Scholar : PubMed/NCBI
17	McGown AT and Fox BW: Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des. 3:249–254. 1989.PubMed/NCBI
18	Carr M, Greene LM, Knox AJ, Lloyd DG, Zisterer DM and Meegan MJ: Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects. Eur J Med Chem. 45:5752–5766. 2010.
19	O’Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM and Meegan MJ: Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. J Med Chem. 53:8569–8584. 2010.PubMed/NCBI
20	Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O’Connor L, Carr M, Keely NO, O’Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ and Zisterer DM: The vascular targeting agent combretastatin-A4 and a novel cis-restricted {beta}-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. J Pharmacol Exp Ther. 335:302–313. 2010.PubMed/NCBI
21	Greene LM, Carr M, Keeley NO, Lawler M, Meegan MJ and Zisterer DM: BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted β-lactam analogue in human cancer cells. Int J Mol Med. 27:715–23. 2011. View Article : Google Scholar : PubMed/NCBI
22	Nathwani SM, Butler S, Meegan MJ, Campiani G, Lawler M, Williams DC and Zisterer DM: Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines. Cancer Chemother Pharmacol. 65:289–300. 2010. View Article : Google Scholar : PubMed/NCBI
23	Auerbach R, Lewis R, Shinners B, Kubai L and Akhtar N: Angiogenesis assays: a critical overview. Clin Chem. 49:32–40. 2003. View Article : Google Scholar : PubMed/NCBI
24	Kubota Y, Kleinman HK, Martin GR and Lawley TJ: Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol. 107:1589–1598. 1988. View Article : Google Scholar : PubMed/NCBI
25	Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
26	Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003.
27	Hughes L, Malone C, Chumsri S, Burger AM and McDonnell S: Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis. 25:549–557. 2008. View Article : Google Scholar : PubMed/NCBI
28	Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA and Schwartz EL: Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 1:1191–1200. 2002.PubMed/NCBI
29	Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A and Dammacco F: Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 94:4143–4155. 1999.PubMed/NCBI
30	Tozer GM, Kanthou C, Parkins CS and Hill SA: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 83:21–38. 2002. View Article : Google Scholar : PubMed/NCBI
31	Pasquier E, Honore S and Braguer D: Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat. 9:74–86. 2006. View Article : Google Scholar : PubMed/NCBI
32	Kerbel RS: Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 13:31–36. 1991. View Article : Google Scholar
33	Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL and Sood AK: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 67:281–288. 2007. View Article : Google Scholar : PubMed/NCBI
34	Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihei Y, Suga Y, Morinaga Y, Akiyama Y and Tsuji T: Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg Med Chem Lett. 8:3153–3158. 1998.PubMed/NCBI
35	Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinski-Mozng N, Frost D, Rosenberg SH and Sham HL: Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem. 45:1697–1711. 2002. View Article : Google Scholar
36	Barrett I, Carr M, O’Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM and Meegan MJ: Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects. J Enzyme Inhib Med Chem. 25:180–194. 2010. View Article : Google Scholar
37	Burns CJ, Fantino E, Powell AK, Shnyder SD, Cooper PA, Nelson S, Christophi C, Malcontenti-Wilson C, Dubljevic V, Harte MF, Joffe M, Phillips ID, Segal D, Wilks AF and Smith GD: The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo. J Pharmacol Exp Ther. 339:799–806. 2011. View Article : Google Scholar : PubMed/NCBI
38	Böhle AS, Leuschner I, Kalthoff H and Henne-Bruns D: Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer. 87:838–843. 2000.PubMed/NCBI
39	Wang J, Lou P, Lesniewski R and Henkin J: Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 14:13–19. 2003. View Article : Google Scholar : PubMed/NCBI
40	Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ and Sukhatme VP: Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer. 113:490–498. 2005. View Article : Google Scholar : PubMed/NCBI
41	Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C and Braguer D: Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 65:2433–2440. 2005. View Article : Google Scholar : PubMed/NCBI
42	Pourroy B, Honoré S, Pasquier E, Bourgarel-Rey V, Kruczynsk A, Briand C and Braguer D: Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res. 66:3256–3263. 2006. View Article : Google Scholar : PubMed/NCBI
43	Kanthou C, Greco O, Stratford A, Cook I, Knight R, Benzakour O and Tozer G: The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol. 165:1401–1411. 2004. View Article : Google Scholar : PubMed/NCBI
44	Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY and Smulson ME: Induction of apoptosis in proliferating human endothelial cells by tumour-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58:4510–4514. 1998.PubMed/NCBI
45	Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR and Al-Katib AM: Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res. 8:2735–2741. 2002.PubMed/NCBI
46	Ding X, Zhang Z, Li S and Wang A: Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells. Oncol Res. 19:303–309. 2011. View Article : Google Scholar : PubMed/NCBI
47	Greene LM, O’Boyle NM, Nolan DP, Meegan MJ and Zisterer DM: The vascular targeting agent combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells. Biochem Pharmacol. 84:612–624. 2012. View Article : Google Scholar : PubMed/NCBI
48	O’Boyle NM, Carr M, Greene LM, Keely NO, Knox AJ, McCabe T, Lloyd DG, Zisterer DM and Meegan MJ: Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe. Eur J Med Chem. 46:4595–4607. 2011.
49	Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29:15–18. 2002. View Article : Google Scholar : PubMed/NCBI
50	Conn G, Soderman DD, Schaeffer MT, Wile M, Hatcher VB and Thomas KA: Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc Natl Acad Sci USA. 87:1323–1327. 1990. View Article : Google Scholar : PubMed/NCBI
51	Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R and Taraboletti G: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 2:1843–1849. 1996.PubMed/NCBI
52	Avramis IA, Kwock R and Avramis VI: Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res. 21:2281–2286. 2001.
53	Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM and Polverini PJ: Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 61:2183–2188. 2001.PubMed/NCBI
54	Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA. 99:4349–4354. 2002. View Article : Google Scholar : PubMed/NCBI
55	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
56	Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M and Altieri DC: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62:2462–2467. 2002.PubMed/NCBI
57	Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B and Chaplin DJ: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61:6413–6422. 2001.PubMed/NCBI
58	Tozer GM, Kanthou C and Baguley BC: Disrupting tumour blood vessels. Nat Rev Cancer. 5:423–435. 2005. View Article : Google Scholar : PubMed/NCBI
59	Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C and Rafii S: Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 115:2992–3006. 2005. View Article : Google Scholar
60	Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B and Hill SA: Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol. 81:S12–S20. 2008. View Article : Google Scholar : PubMed/NCBI